@article {Guan2000547，笔者= {关，卫杰和梁，文华和赵忆和梁恒锐和陈梓生和李易敏和刘，肖青，陈，茹冲和唐春李和王，道，欧，春权，李，李，陈，平欣和桑，凌和王炜和李，建辅，李，蔡辰和欧，李民，程，博雄，山和Ni，郑毅和翔杰与胡，俞和刘，雷和山，康和雷，春亮，彭，宜香和伟李，刘，勇和胡，亚华，彭鹏和王，建明和刘，济阳和陈，钟，李，刚和郑，志坚和邱韶琴，罗，杰爷，常江，朱邵勇和郑，林龄，叶，冯，李，施跃和郑，金平，张，傩福，钟，南山和他，建星}，编辑= {，}，标题= {合并症与COVID-19在中国的对1590例患者的影响：在全国范围内分析}，体积= {55}，数量= {5}，elocation-ID = {2000547}，年= {2020}，DOI = {10.1183 / 13993003.00547-2020}，出版商= {欧洲呼吸学会188bet官网地址}，抽象= {背景冠状病毒病2019（COVID-19）疫情发展迅速worldwide.Objective要通过评估严重不良后果的风险，患者COVID-19分层合并症status.Methods我们分析的数据来自1590例实验室确认的31个省住院患者从575家医院/自治区/在中国大陆省级直辖市12月11日到2020年一月期间2019 31我们分析了复合终点，其中包括的入院重症监护病房，有创通气或死亡。到达复合终点的风险是根据comorbidities.Results的存在和数量的平均年龄为48.9岁，686（42.7 \％）患者均为女性相比。 Severe cases accounted for 16.0\% of the study population. 131 (8.2\%) patients reached the composite end-points. 399 (25.1\%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9\%), followed by diabetes (8.2\%). 130 (8.2\%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95\% CI) 2.681 (1.424{\textendash}5.048)), diabetes (1.59 (1.03{\textendash}2.45)), hypertension (1.58 (1.07{\textendash}2.32)) and malignancy (3.50 (1.60{\textendash}7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95\% CI) was 1.79 (1.16{\textendash}2.77) among patients with at least one comorbidity and 2.59 (1.61{\textendash}4.17) among patients with two or more comorbidities.Conclusion Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.The presence and number of comorbidities predict clinical outcomes of COVID-19 http://bit.ly/3b9ibw5}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/55/5/2000547}, eprint = {//www.qdcxjkg.com/content/55/5/2000547.full.pdf}, journal = {European Respiratory Journal} }